Physician profile

Sara Albagoush

Hospitalist · Omaha, NE

NPI 1265957021

$451.68

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Hospitalist

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$21.53

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $199.82 2020-2023
E.R. Squibb & Sons, L.L.C. $77.32 2020-2022
Janssen Pharmaceuticals, INC $62.07 2020-2021
Ucb, INC. $20.07 2021
Alexion Pharmaceuticals, INC. $18.03 2022
Astrazeneca Pharmaceuticals LP $17.60 2021
Janssen Scientific Affairs, LLC $16.99 2021
Ultragenyx Pharmaceutical INC. $14.29 2021
Amgen INC. $13.61 2021
Boehringer Ingelheim Pharmaceuticals, INC. $11.88 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sara Albagoush

$451.68

in general payments reported 2019-2025

Years
2020-2023
Top company
Pfizer INC.

https://glasscript.com/doctor/4176413/sara-albagoush

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.